Demonstrated that P2B001 provides benefits comparable with commercially used doses of marketed pramipexole-ER (PramiER) while minimizing associated daytime sleep–related and…
-- Blocking of α5β1 integrin has been shown to improve motor function and increase survival in the SOD1G93A mouse model of…
Dr. Silver's life work, culminating in NervGen's NVG-291, is currently in a Phase 1b/2a clinical trial for individuals with spinal…
Company Introduces Multimedia Resources to Bring Awareness of SADLAVAL, QC / ACCESSWIRE / November 8, 2023 / As daylight saving…
TARRYTOWN, NY / ACCESSWIRE / November 7, 2023 / PaxMedica, Inc. (NASDAQ:PXMD), a biopharmaceutical company focused on advancing treatments for…
Toronto, Ontario--(Newsfile Corp. - November 2, 2023) - Red Light Holland Corp. (CSE: TRIP) (FSE: 4YX) (OTCQB: TRUFF) ("Red Light…
Revenue of $2.24 billion, up 9% on both a Reported and Organic1 basisYear-over-year revenue growth in all segments on both…
LAVAL, QC / ACCESSWIRE / October 12, 2023 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) will release its third-quarter financial results…
A global licensing agreement has been signed for the development and commercialization of SOFIE’s two investigational Gallium-68 and Fluorine-18 Fibroblast…
SANTA ANA, Calif., Oct. 11, 2023 (GLOBE NEWSWIRE) -- NKGen Biotech Inc. (Nasdaq: NKGN) (“NKGen” or the “Company”), a clinical-stage…